Radaelli et al. selected a NB cell line resistant to lornatinib (CLB-GA-LR1000) to perform a whole-exome sequencing and proteomic profiling of these cells and revealed a truncating NF1 mutation and hyperactivation of EGFR and ErbB4 [206]. This evidence concerns the gene EGFR and neuroblastoma.